Light & Bio Unveils DFZ-1000: Revolutionizing Alzheimer’s Early Screening with Single-Molecule Fluorescence Immunoassay Technology

On March 22, a technological revolution that is set to transform the paradigm of Alzheimer’s disease (AD) detection was unveiled in Conference Room 7-204 at the Hangzhou Grand Convention and Exhibition Center. At Light and Life’s new product launch event, themed “Precision Testing, Safeguarding Memories,” authoritative experts from academia, industry, research, and clinical practice gathered to officially release the DFZ-1000 Fully Automated Single-Molecule Fluorescence Immunoassay Analyzer, ushering in a new era of femtogram-level precision testing for early AD screening.

The press conference commenced with an academic keynote by Researcher Dong Wenfei from the Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences. He stated, “Single-molecule detection technology has broken through traditional detection limits, increasing the sensitivity of blood-based Alzheimer’s disease (AD) biomarker testing by three orders of magnitude. This represents not only a technological innovation but also a redefinition of the AD diagnosis and treatment paradigm.”

Yu Haibo, General Manager of Shenzhen Yingkai Biotechnology, stated that the strategic partnership between Yingkai Biotechnology and Light and Life will accelerate the market launch of DFZ-1000. “By combining automated platforms with ultra-sensitive technology, we are committed to transitioning Alzheimer’s disease (AD) blood testing from research to clinical practice, thereby making the large-scale implementation of precision medicine a reality.”

Dr. He Hao, founder of Light and Life, unveiled the core technology on-site: DFZ-1000 employs rare-earth upconversion luminescent probe technology combined with convolutional neural network algorithms to achieve fg/mL-level detection sensitivity. The device delivers the first test results within 15 minutes and supports simultaneous detection of key biomarkers such as Aβ42/Aβ40 and p-Tau217.

“The DFZ-1000 is not merely an instrument, but a paradigm shift in Alzheimer’s disease (AD) prevention and treatment,” stated Dr. He Hao. “It provides a golden window for intervention among asymptomatic high-risk populations, facilitating closed-loop management centered on ‘early screening, early diagnosis, and early treatment.’”

At the press conference, the unveiling ceremony of the DFZ-1000 brought the atmosphere to a climax. This innovative device, certified under Guangdong Medical Device Registration No. 20252220342, marks a technological breakthrough by Light and Life in the field of high-end immunoassay. Its application scenarios cover:

● Screening for high-risk populations:Provide early pathological signal monitoring for individuals with normal cognition but carrying genetic risks or having a family history;

● Differential Diagnosis of Mild Cognitive Impairment (MCI):Precise differentiation of Alzheimer’s disease–derived mild cognitive impairment (MCI) from other reversible cognitive impairments through dynamic ratio analysis of Aβ and Tau proteins;

● Drug R&D Support:Provide real-time pharmacodynamic assessment tools for clinical trials of anti-amyloid drugs to shorten the R&D cycle.

During the academic sharing session, Professor Wang Rong, Director of the Central Laboratory at Xuanwu Hospital of Capital Medical University, systematically elucidated advances in research on fluid biomarkers for Alzheimer’s disease (AD): “Our multicenter study confirmed that peripheral blood p-Tau217 levels showed 91% concordance with cerebrospinal fluid (CSF) testing. The femtogram-level sensitivity of DFZ-1000 enables seamless alignment between the detection window of blood-based assays and CSF testing.”

Dr. Jin He from Xuanwu Hospital vividly demonstrated the value of technological innovation through typical clinical cases: "A 68-year-old patient was found to have an abnormal Aβ42/Aβ40 ratio via DFZ-1000 testing, even while their scores on the MMSE scale remained within the normal range. Subsequent PET verification confirmed early changes associated with Alzheimer's disease (AD), allowing for intervention three years earlier than traditional diagnostic methods would have permitted."

Amidst the technological reverberations along the Qiantang River, Light and Life leverages the DFZ-1000 as a fulcrum to drive innovation in the Alzheimer’s disease (AD) prevention and control system. As Professor Wang Rong stated, “When detection technology breaks through the femtogram threshold, we usher in not only a diagnostic revolution but also a new era of proactive cognitive health management.”

As an innovative enterprise in the field of single-molecule detection technology in China, Light and Life possesses core technologies including nano-scale ultra-bright rare-earth upconversion luminescent probes and single-particle imaging systems, and has developed a cost-effective, ultra-sensitive single-molecule detection technology platform. The company has established multiple product pipelines for early screening of prostate cancer, detection of cardiovascular injury, early screening of preeclampsia, and early screening of Alzheimer’s disease, while continuously advancing the exploration, translation, and market expansion of new single-molecule detection projects.

This technology gala, a convergence of wisdom, not only marks China’s overtaking maneuver in the field of ultra-sensitive detection but also heralds the advent of an era in which Alzheimer’s disease (AD) prevention and control are shifting from passive treatment to proactive health management. Leveraging the power of technological innovation, Light and Life is contributing a Chinese solution to cracking the “memory code” for humanity.